The market is acting well these days and so is our April recommendation. It’s a small medical company with enormous growth potential, focused on helping larger companies deliver their cancer-killing drugs efficiently to the right locations. Some of our readers may find the complex medical terminology of the report challenging, but in the long run, we believe both the reading and the investing will bring rewards.
